SCHEMBL16014680

SCHEMBL16014680

COc1ccc(CN(C)c2nc(N)nn2Cc2ccc(OC)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
ADORA2A P29274 2/20 0.45
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ATM Q13315 1/20 0.40
PDE8B O95263 2/20 0.40
APLNR P35414 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
ALOX15 P16050 2/20 0.38
HSP90AB1 P08238 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15556570 0.88 ALDH1A1 (0.44) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4
SCHEMBL18856594 0.84 NPBWR1 (0.43) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4
SCHEMBL15983823 0.83 ALDH1A1 (0.40) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4
SCHEMBL18723713 0.82 ALDH1A1 (0.42) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4
SCHEMBL16023965 0.81 ALDH1A1 (0.41) ALDH1A1ADORA2AAPLNRSMN1; SMN2HTT
SCHEMBL16014406 0.79 MAPT (0.46) ALDH1A1ADORA2AAPLNRSMN1; SMN2HTT
SCHEMBL16014490 0.79 CYP2D6 (0.47) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4
SCHEMBL17403441 0.77 ACP1 (0.44) ALDH1A1ADORA2ASMN1; SMN2NPSR1LMNA
SCHEMBL16023894 0.76 SMN1; SMN2 (0.38) ALDH1A1ADORA2ASMN1; SMN2MAPTNPBWR1
SCHEMBL20194918 0.74 CYP2D6 (0.47) ALDH1A1ADORA2ACYP2D6CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2964626-A1 ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2016-01-13 EP disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
US-20160002180-A1 ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (US) 2016-01-07 US disclosed
WO-2014135472-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002180-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS ALDH1A1 204/4885ADORA2A 1473/4885CYP2D6 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.